Genetics
Showing 51-100 of 380 Results
-
Howard Y. Chang, MD, PhD
Virginia and D. K. Ludwig Professor of Cancer Research, Professor of Genetics and, by courtesy, of Pathology
On Leave from 12/16/2024 To 12/15/2026Current Research and Scholarly InterestsOur research is focused on how the activities of hundreds or even thousands of genes (gene parties) are coordinated to achieve biological meaning. We have pioneered methods to predict, dissect, and control large-scale gene regulatory programs; these methods have provided insights into human development, cancer, and aging.
-
Mike Cherry
Professor (Research) of Genetics, Emeritus
Current Research and Scholarly InterestsMy research involves identifying, validating and integrating scientific facts into encyclopedic databases essential for research and scientific education. Published results of scientific experimentation are a foundation of our understanding of the natural world and provide motivation for new experiments. The combination of in-depth understanding reported in the literature with computational analyses is an essential ingredient of modern biological research.
-
Stanley N. Cohen, MD
Kwoh-Ting Li Professor in the School of Medicine, Professor of Genetics and of Medicine
On Partial Leave from 06/04/2025 To 07/16/2026Current Research and Scholarly InterestsWe study mechanisms that affect the expression and decay of normal and abnormal mRNAs, and also RNA-related mechanisms that regulate microbial antibiotic resistance. A small bioinformatics team within our lab has developed knowledge based systems to aid in investigations of genes.
-
Le Cong
Associate Professor of Pathology (Pathology Research) and of Genetics
Current Research and Scholarly InterestsOur lab develops gene-editing technologies like novel CRISPR systems and large gene insertion techniques for gene and cell therapy. We also leverage these gene-editing tools for single-cell functional screening to probe mechanisms of cancer, immunological, and aging-associated diseases. To accelerate our work, we integrate AI and machine learning to design and evolve therapeutic RNAs/proteins, and build AI-XR co-scientists like LabOS that bridge AI computation and biomedical experimentation.
-
David Cox
Assistant Professor of Genetics and, by courtesy, of Medicine (Hematology)
BioDavid Cox is an Assistant Professor of Genetics and by courtesy of Medicine (Hematology) at Stanford University and Principal Investigator of the Cox Lab (coxlab.bio), which is opening in July 2025. He is also a ChEM-H Institute Scholar and Chan Zuckerberg Biohub Investigator.
He completed his undergraduate studies in biology at Stanford University, where he worked with Irving Weissman on understanding how the innate immune system recognizes cancer cells. He then entered the Harvard-MIT MD-PhD program, earning his MD from the Harvard-MIT program in Health Sciences and Technology (HST) and his PhD in biology from MIT. His doctoral dissertation with Feng Zhang focused on the discovery and development of CRISPR-Cas enzymes as novel DNA and RNA editing tools. During his final year of medical school, he worked as a visiting scientist with David Baker, where he initiated efforts to design sequence-specific DNA binding proteins de novo.
Following medical school, Cox completed internal medicine residency and a clinical fellowship in hematology at Stanford, where he concurrently conducted postdoctoral research in Rhiju Das's lab. In the Das lab, he fine-tuned large language models for RNA structure prediction and developed new methods for highly multiplexed detection of RNA-protein interactions.
His current list of publications and patents is available here: https://scholar.google.com/citations?user=ZohHoFYAAAAJ&hl=en&oi=ao -
Christina Curtis
RZ Cao Professor and Professor of Genetics
Current Research and Scholarly InterestsThe Curtis laboratory for Cancer Computational and Systems Biology is focused on the development and application of innovative experimental, computational, and analytical approaches to improve the diagnosis, treatment, and early detection of cancer.
-
Kyle Gabriel Daniels
Assistant Professor of Genetics and, by courtesy, of Neurosurgery (Adult Neurosurgery)
BioKyle obtained his BS in Biochemistry from the University of Maryland College Park in 2010, conducting undergraduate research with Dr. Dorothy Beckett, PhD. He obtained his PhD in Biochemistry with a certificate in Structural Biology and Biophysics. His dissertation is titled "Kinetics of Coupled Binding and Conformational Change in Proteins and RNA" and was completed in the laboratory of Dr. Terrence G. Oas, PhD. Kyle performed postdoctoral training with Dr. Wendell A. Lim, PhD at UCSF studying how CAR T cell phenotype is encoded by modular signaling motifs within chimeric antigen receptors.
Kyle's lab is interested in harnessing the principles of modularity to engineer receptors and gene circuits to control cell functions.
The lab will use synthetic biology, medium- and high-throughput screens, and machine learning to: (1) Engineer immune cells to achieve robust and durable responses against various cancer targets, (2) Coordinate behavior of multiple engineered cell types in cancer, autoimmune disease, and payload delivery, (3) Control survival, proliferation, and differentiation of hematopoietic stem cells (HSCs) and immune cells, and (4) Explore principles of modularity related to engineering receptors and gene circuits in mammalian cells. -
Ronald W. Davis
Professor of Biochemistry and of Genetics
Current Research and Scholarly InterestsWe are using Saccharomyces cerevisiae and Human to conduct whole genome analysis projects. The yeast genome sequence has approximately 6,000 genes. We have made a set of haploid and diploid strains (21,000) containing a complete deletion of each gene. In order to facilitate whole genome analysis each deletion is molecularly tagged with a unique 20-mer DNA sequence. This sequence acts as a molecular bar code and makes it easy to identify the presence of each deletion.
-
Jesse Engreitz
Assistant Professor of Genetics
Current Research and Scholarly InterestsRegulatory elements in the human genome harbor thousands of genetic risk variants for common diseases and could reveal targets for therapeutics — if only we could map the complex regulatory wiring that connects 2 million regulatory elements with 21,000 genes in thousands of cell types in the human body.
We combine experimental and computational genomics, biochemistry, molecular biology, and genetics to assemble regulatory maps of the human genome and uncover biological mechanisms of disease. -
Rongxin Fang
Assistant Professor of Neurosurgery and, by courtesy, of Genetics
BioRongxin Fang received his Ph.D. in Bioinformatics and Systems Biology from the University of California, San Diego, under the mentorship of Bing Ren (2015–2019). During his doctoral training, he developed high-throughput genomic technologies and computational tools to map the structure and activity of the mammalian genome at large scale and single-cell resolution. He then applied these approaches to investigate how cis-regulatory elements - such as enhancers - control gene expression and drive the diverse transcriptional programs underlying cellular diversity in the mammalian brain. As an HHMI–Damon Runyon Postdoctoral Fellow at Harvard University (2019–2024), he worked with Xiaowei Zhuang. Rongxin developed and applied genome-scale, volumetric 3D transcriptome imaging methods to map the molecular and cellular architecture of the mammalian brain across evolution and aging. He also contributed to the collaboration with Adam Cohen and Catherine Dulac to integrate transcriptome imaging with functional neuronal imaging, identifying neuronal populations in the animal brain that underlie specific brain functions.
